Herbert Skip Virgin
2019
In 2019, Herbert Skip Virgin earned a total compensation of $2M as Executive Vice President, Research and Chief Scientific Officer at Vir Biotechnology, a 9% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $248,400 |
|---|---|
| Option Awards | $1,018,963 |
| Salary | $617,500 |
| Other | $84,000 |
| Total | $1,968,863 |
Virgin received $1M in option awards, accounting for 52% of the total pay in 2019.
Virgin also received $248.4K in non-equity incentive plan, $617.5K in salary and $84K in other compensation.
Rankings
In 2019, Herbert Skip Virgin's compensation ranked 6,007th out of 13,971 executives tracked by ExecPay. In other words, Virgin earned more than 57.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,007 out of 13,971 | 57th |
Division Manufacturing | 2,251 out of 5,695 | 61st |
Major group Chemicals And Allied Products | 813 out of 2,194 | 63rd |
Industry group Drugs | 686 out of 1,880 | 64th |
Industry Biological Products, Except Diagnostic Substances | 162 out of 389 | 58th |
Source: SEC filing on April 6, 2020.
Virgin's colleagues
We found two more compensation records of executives who worked with Herbert Skip Virgin at Vir Biotechnology in 2019.